Stryker Corporation (SYK) Position Reduced by Nomura Asset Management Co. Ltd.
Nomura Asset Management Co. Ltd. trimmed its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 404,469 shares of the medical technology company’s stock after selling 5,643 shares during the quarter. Nomura Asset Management Co. Ltd. owned about 0.11% of Stryker worth $57,442,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also bought and sold shares of the stock. Acrospire Investment Management LLC purchased a new position in shares of Stryker in the 2nd quarter worth about $111,000. Motco boosted its holdings in shares of Stryker by 50.7% in the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 278 shares in the last quarter. San Francisco Sentry Investment Group CA boosted its holdings in shares of Stryker by 47.8% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 325 shares in the last quarter. Bruderman Asset Management LLC purchased a new position in shares of Stryker in the 2nd quarter worth about $150,000. Finally, James Investment Research Inc. purchased a new position in shares of Stryker in the 2nd quarter worth about $155,000. Institutional investors and hedge funds own 74.97% of the company’s stock.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the transaction, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.40% of the company’s stock.
Stryker Corporation (NYSE:SYK) traded down $3.51 on Tuesday, reaching $152.36. The company’s stock had a trading volume of 1,351,000 shares, compared to its average volume of 1,182,374. The company has a market cap of $58,332.41, a price-to-earnings ratio of 24.70, a price-to-earnings-growth ratio of 2.45 and a beta of 0.78. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. Stryker Corporation has a fifty-two week low of $111.22 and a fifty-two week high of $160.62.
Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.02. The business had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. Stryker’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.39 EPS. analysts anticipate that Stryker Corporation will post 6.47 earnings per share for the current fiscal year.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).
Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.